Clinical Development Innovation in Rare Diseases: Overcoming Barriers to Successful Delivery of A Randomised Clinical Trial in Alkaptonuria
Ranganath LR1,2*, Sireau N3
1Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Prescot Street, Liverpool, L7 8XP
2Department of Musculoskeletal Biology, University of Liverpool, L7 8TX
3The Alkaptonuria Society, Cambridge, UK
Ranganath LR, Sireau N. Clinical Development Innovation in Rare Diseases: Overcoming Barriers to Successful
Delivery of A Randomised Clinical Trial in Alkaptonuria. J Clin Med Current Res. (2022);2(2): 1-3
Abstract
Alkaptonuria (AKU) (OMIM#203500) is a rare inherited disorder due to deficiency of homogentisate dioxygenase
with resultant accumulation of homogentisic acid, occurring with a worldwide frequency of 1 in 100,000 to 250,000 [1].
Keywords
Alkaptonuria, nitisinone, homogentisic acid, SONIA 2, DevelopAKUre